Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Mcgraw, Kathy L ^a   Basiorka, Ashley A ^a   Johnson, Joseph O ^a   Clark, Justine ^a   Caceres, Gisela ^a   Padron, Eric ^a   Heaton, Ruth ^b   Ozawa, Yukiyasu ^c   Wei, Sheng ^a   Sokol, Lubomir ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; LENALIDOMIDE; PROTEIN KINASE LYN; RECOMBINANT ERYTHROPOIETIN; RHO KINASE; STAT5 PROTEIN; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; AMIDE; IMMUNOLOGIC FACTOR; PYRIDINE DERIVATIVE; THALIDOMIDE;

ACTIN FILAMENT; ACTIN POLYMERIZATION; ARTICLE; CELL COUNT; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOLOGICAL SYNAPSE; LIPID RAFT; MEGAKARYOCYTE; MONOCYTE; MYELODYSPLASTIC SYNDROME; PROTEIN AGGREGATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; DRUG EFFECTS; DRUG SCREENING; FEMALE; MALE; METABOLISM; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PHYSIOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VERY ELDERLY;

ACTINS; AGED; AGED, 80 AND OVER; AMIDES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ERYTHROID PRECURSOR CELLS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MEMBRANE MICRODOMAINS; MYELODYSPLASTIC SYNDROMES; PROTEIN MULTIMERIZATION; PYRIDINES; RECEPTORS, ERYTHROPOIETIN; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84939142234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114249     Document Type: Article

References (31)

1. Hoefsloot LH, van Amelsvoort MP, Broeders LC, van der Plas DC, van Lom K, et al. (1997) Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 89: 1690-1700.
2. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, et al. (2008) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS medicine 5: e35.
3. Fuhler GM, Blom NR, Coffer PJ, Drayer AL, Vellenga E (2007) The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation. Journal of leukocyte biology 81: 449-457.
4. McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, et al. (2012) Erythropoietin receptor signaling is membrane raft dependent. PloS one 7: e34477.
5. Xavier R, Brennan T, Li Q, McCormack C, Seed B (1998) Membrane compartmentation is required for efficient T cell activation. Immunity 8: 723-732.
6. Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nature review molecular cell biology 1: 31-39.
7. Kabouridis PS, Jury EC (2008) Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Letters 582: 3711-3718.
8. Lou Z, Billadeau DD, Savoy DN, Schoon RA, Leibson PJ (2001) A role for a RhoA/ROCK/LIM-kinase pathway in the regulation of cytotoxic lymphocytes. Journal of immunology 167: 5749-5757.
9. Xu Y, Li J, Ferguson GD, Mercurio F, Khambatta G, et al. (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114: 338-345.
10. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. The New England journal of medicine 352: 549-557.
11. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, et al. (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111: 86-93.
12. List A, Dewald G, Bennett J, Giagounidis A, Raza A, et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England journal of medicine 355: 1456-1465.
13. Harder T, Scheiffele P, Verkade P, Simons K (1998) Lipid domain structure of the plasma membrane revealed by patching of membrane components. The journal of cell biology 141: 929-942.
14. Jobling MG (2002) Mutational Analysis of Ganglioside GM1-Binding Ability, Pentamer Formation, and Epitopes of Cholera Toxin B (CTB) Subunits and CTB/Heat-Labile Enterotoxin B Subunit Chimeras. Infection and Immunity 70: 1260-1271.
15. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, et al. (1994) Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein science : A publication of the Protein Society 3: 166-175.
16. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, et al. (2013) GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 121: 5068- 5077.
17. Narla A, Dutt S, McAuley JR, Al-Shahrour F, Hurst S, et al. (2011) Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood 118: 2296-2304.
18. Tomai F, Toma A, Chevret S, Kosmider O, Delaunay J, et al. (2013) A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. Journal of Clinical Oncology Abstract 7002.
19. Eisenmann KM, West RA, Hildebrand D, Kitchen SM, Peng J, et al. (2007) T cell responses in mammalian diaphanous-related formin mDia1 knock-out mice. The Journal of biological chemistry 282: 25152-25158.
20. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, et al. (2011) Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of biological chemistry 286: 25211-25223.
21. Sundaravel S, Bhagat T, Schinke C, Ebenezer D, Liu H, et al. (2012) Aberrant expression of DOCK4 leads to disruption of the F-actin skeleton and altered membrane stability in MDS erythroblasts and mature erythrocytes. Blood (ASH Annual Meeting Abstracts) 120.
22. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
23. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, et al. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK 26: 2326-2335.
24. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, et al. (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343: 305-309.
25. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, et al. (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 164: 811- 821.
26. Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, et al. (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343: 301-305.
27. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, et al. (2012) Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene.
28. Deng S, Huang C (2014) E3 ubiquitin ligases in regulating stress fiber, lamellipodium, and focal adhesion dynamics. Cell Adh Migr 8: 49-54.
29. Wu S, Wolf DA (2009) Destruction of RhoA CULtivates actin. Mol Cell 35: 735-736.
30. Torrino S, Visvikis O, Doye A, Boyer L, Stefani C, et al. (2011) The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1. Developmental cell 21: 959-965.
31. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, et al. (2002) Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 21: 8804-8816.